Format

Send to

Choose Destination
Angiology. 2019 Sep;70(8):737-746. doi: 10.1177/0003319719845185. Epub 2019 Apr 28.

GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis.

Author information

1
1 Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD, USA.
2
2 Department of Medicine, St Agnes Hospital, Baltimore, MD, USA.
3
3 Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
4
4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
5
5 Department of Medicine, St Luke's Hospital, Chesterfield, MO, USA.
6
6 Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
7
7 Laboratory Corporation of America Holdings (LabCorp), Morrisville, NC, USA.
8
8 Division of Cardiovascular Medicine, University of Wisconsin, Madison, WI, USA.

Abstract

GlycA, a composite biomarker of systemic inflammation, is associated with cardiovascular disease (CVD) and mortality, but its relationship with peripheral artery disease (PAD) is unknown. We assessed whether plasma GlycA is associated with ankle-brachial index (ABI), carotid plaque (CP), and incident clinical PAD among 6466 Multi-Ethnic Study of Atherosclerosis participants without CVD at baseline. GlycA, ABI, and CP were measured at baseline. Both ABI and CP were remeasured at 10 years. Incident clinical PAD was ascertained from hospital records. We used logistic, Cox, and linear mixed regression models adjusted for demographic and lifestyle factors. Mean (standard deviation, SD) was 62 (10) years for age and 381 (61) µmol/L for GlycA; 53% were women. GlycA was associated with both prevalent low ABI ≤0.8 (prevalence odds ratio [95% confidence interval, CI] per SD increment in GlycA, 1.65 [1.39-1.97]) and CP (1.19 [1.11-1.27]) at baseline. There were no significant associations of GlycA with incident low ABI, incident CP, or 10-year change in ABI or CP score. We identified 110 incident cases of PAD after 79 590 person-years. The hazard ratio (95% CI) of incident PAD per SD increment in GlycA was 1.38 (1.14-1.66). In conclusion, GlycA was associated with prevalent low ABI, prevalent CP, and incident PAD after a median of 14 years.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00005487.

KEYWORDS:

GlycA; ankle–branchial index; carotid plaque; inflammation; peripheral artery disease

PMID:
31030528
PMCID:
PMC6663563
[Available on 2020-09-01]
DOI:
10.1177/0003319719845185
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center